POSTER: CT-107 Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axicel), as Second-Line (2L) Treatment of Large B-Cell Lymphoma (LBCL)
Makaleler > Tam Makale · 2023
Yazarlar: Matthew Lunning, Kristen A. Deger, Fei Fei Liu, Ahmed Elsada, Sven L. Klijn, Michal Litkiewicz, Conrado Franco-Villalobos, Sonja V. Sorensen
Clinical Lymphoma Myeloma and Leukemia, Uluslararası, Wos, 2023, cilt 23, ss S228-S228